Bluebird Bio acquires manufacturing facility in North Carolina and executes multiple global supply agreements to enhance ability to deliver gene therapies to patients. Bluebird Bio, Inc., a clinical-stage company developing potentially transformative gene and cell therapies for severe genetic diseases and T cell-based immunotherapies for cancer, has acquired a 125,000-square foot manufacturing facility in Durham,…